: iStockAnalyst.com Symbols Feed

Biostar Raises $3.6 Million

Fri, 06 Nov 2009 17:26:18 GMT

Biostar Pharmaceuticals has completed a private placement that raised $3.6 million in new capital. Biostar will use the proceeds to complete its new raw materials processing facility. By taking its raw material production in house, Biostar will lower costs and ensure its product quality. Biostar plans to sell excess raw materials to other pharmaceutical companies in the Shaanxi province.[More...]

Bulls Back On Track?

Fri, 06 Nov 2009 16:21:18 GMT

Good morning. With chants of "Dow 10K… Dow 10K" once again rising from the streets at the corner of Broad and Wall yesterday, it is easy to believe that the bulls are back on track and that we'll soon be looking at new highs for the stock market. And when reviewing the data inputs to yesterday's 204 point romp, it is also easy to don the Dow10K hat once again and join in on the celebration.[More...]

Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules

Fri, 06 Nov 2009 13:52:50 GMT

Ford's 2,215 page 2007 master contract with the UAW 1941 UAW-Ford contract[More...]

King Beats, But Earnings Down

Thu, 05 Nov 2009 20:08:54 GMT

King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses.[More...]

Your Kind of Day?

Thu, 05 Nov 2009 19:06:48 GMT

As a rule, I try not to read too terribly much into a "Fed Day" as there is usually a big batch of volatility that may or may not mean much of anything come the dawn of the next day. Maybe, it's just me. Or maybe there are others that find themselves inclined to simply stand aside and watch the nuttiness from the sidelines on "Fed Days." But in any event, the volatility after a Fed announcement, while fun to watch, may not be telling as to what to expect in the future.[More...]

The Dollar-Proof Portfolio

Thu, 05 Nov 2009 17:31:14 GMT

Don't put off this important piece of the financial-planning process.[More...]

King Pharmaceuticals, Inc (NYSE: KG): Third Quarter Earnings Preview 2009

Thu, 05 Nov 2009 14:35:00 GMT

King Pharmaceuticals, Inc is scheduled to report its fiscal third quarter 2009 financial results on Thursday, November 5, 2009.[More...]

What Investors Should Look for In Today’s Fed Statement

Wed, 04 Nov 2009 13:04:24 GMT

In its continuing efforts to nurture the fragile economic recovery, the U.S. Federal Reserve is widely expected to leave interest rates at record lows when it concludes its meeting today (Wednesday).[More...]

Are Discount Brokers Shares Worth Owning?

Wed, 04 Nov 2009 01:28:03 GMT

The third quarter was a favorable one for the longs. Except for a few short-lived, minor pullbacks stock prices moved higher through the quarter. Stock price volatility declined, takeover activity rose, and risk appetite improved to help the S&P gain 15%.[More...]

Durect Q3 Net Loss Narrows

Fri, 30 Oct 2009 13:49:00 GMT

Durect, a US-based specialty pharmaceutical company, has reported a net loss of $5.54 million, or $0.07 per share, for the third quarter ended September 30, 2009, compared to a net loss of $9.16 million, or $0.11 per share, for the third quarter ended September 30, 2008.
Total revenues were $8.38 million for the third quarter of 2009, compared to $6.63 million for the same quarter of 2008.
Net loss for the nine months ended September 30, 2009 was $21.7 million, or $0.26 per share, compared to a net loss of $25.56 million, or $0.33 per share, for the nine months ended September 30, 2008.

: iStockAnalyst.com Symbols Feed

Biostar Raises $3.6 Million

Bulls Back On Track?

Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules

King Beats, But Earnings Down

Your Kind of Day?

The Dollar-Proof Portfolio

King Pharmaceuticals, Inc (NYSE: KG): Third Quarter Earnings Preview 2009

What Investors Should Look for In Today’s Fed Statement

Are Discount Brokers Shares Worth Owning?

Durect Q3 Net Loss Narrows

City of Wichita to Fight Westar Rate Merger

New York Hedge Fund Penalized for Not Disclosing Interests in Sale

Westar South Customers May Pay for North's Co2 Emissions

Stocks Tumble on Jobs News

King Pharmaceuticals Reports Q1 Net Loss

King Pharmaceuticals Posts $11M Loss

Three Contracts Show Praxair's Global Reach

Reversal of Fortune 500 Boosts Pittsburgh

King Pharmaceuticals to Present at Credit Suisse Healthcare Conference

King Pharmaceuticals to Present at UBS Global Life Sciences Conference

Acura Pharmaceuticals and King Pharmaceuticals Provide Update on Acurox® NDA

BenchmarkJournal.Com Free Analyst Review for ANN, GGB, KG, PFG, IAG and QTM

DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)

Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain

King Pharmaceuticals Reports Second Quarter 2009 Financial Results

Pain Therapeutics Reviews Mid-Year Progress, Reports Second Quarter 2009 Financial Results

Ligand Pharmaceuticals Announces Second Quarter Results

Acura Pharmaceuticals Reports Second Quarter 2009 Financial Results

Form 4 BROUILLETTE FREDERICK For: Aug 13 (10K)

Form 4 BROUILLETTE FREDERICK For: Jun 08 (10K)

Form 4 MOYER CHARLES For: Jun 01 (10K)

Form 4 Carter Eric G For: Mar 23 (10K)

Form 4 MARKISON BRIAN A For: Mar 23 (10K)

Form 4 Elrod James W For: Mar 23 (10K)

Form 4 Squicciarino Joseph For: Mar 20 (10K)

Form 4 MARKISON BRIAN A For: Mar 20 (10K)

Form 4 GREEN JAMES E For: Mar 20 (10K)

Form 4 BRUCE ERIC J For: Mar 20 (10K)